Venus Remedies Ltd

Venus Remedies Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Venus Remedies Ltd

₹ 359 2.62%
28 Jun - close price
venusremedies.com BSE: 526953 NSE: VENUSREM
About

Incorporated in 1989, Venus Remedies
Ltd is a research based pharmaceutical company and an injectable manufacturer[1]

Key Points

Business Overview:[1][2]
VSR is one of the largest manufacturers of meropenem antibiotics in India. It offers a wide range of pharmaceutical products that cater to various therapeutic areas, including anti infective (antibiotics), antimicrobial resistance, oncology, neurology, pain management, skin
& wound care. Company has 800+ marketing authorizations globally, 100+ patents and 90+ product basket which includes formulations such as injectables,
tablets, and topical preparations

Website BSE NSE
  • Market Cap ₹ 479 Cr.
  • Current Price ₹ 359
  • High / Low ₹ 430 / 222
  • Stock P/E 15.7
  • Book Value ₹ 380
  • Dividend Yield 0.00 %
  • ROCE 8.77 %
  • ROE 6.18 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Stock is trading at 0.94 times its book value

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 7.89% over last 3 years.
  • Debtor days have increased from 44.7 to 56.8 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
102 137 193 117 129 155 125 110 149 99 170 131 175
95 118 165 103 121 137 110 103 128 85 157 118 154
Operating Profit 8 19 28 14 7 18 15 7 21 13 13 13 21
OPM % 8% 14% 14% 12% 6% 12% 12% 6% 14% 14% 8% 10% 12%
24 2 3 1 2 1 2 4 3 2 3 2 4
Interest 1 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 9 8 8 8 7 8 9 7 8 7 6 6 6
Profit before tax 22 13 22 7 2 12 8 4 16 8 10 9 19
Tax % -78% -13% -8% -14% 0% 8% 5% 32% 53% 47% 45% 10% 36%
39 15 24 8 2 11 8 3 8 4 5 8 13
EPS in Rs 31.32 10.91 18.05 5.87 1.81 8.30 5.78 1.95 5.64 3.25 4.08 6.13 9.36
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
452 515 443 392 375 355 299 316 511 574 534 575
333 382 356 312 328 312 265 273 464 505 473 514
Operating Profit 118 133 87 80 47 44 34 43 47 69 62 61
OPM % 26% 26% 20% 20% 13% 12% 11% 14% 9% 12% 12% 11%
0 0 1 1 1 1 -4 -5 41 8 10 11
Interest 24 29 41 37 34 35 25 13 13 0 0 0
Depreciation 32 39 45 40 39 33 33 31 34 33 31 26
Profit before tax 63 66 2 3 -25 -23 -28 -6 41 45 40 47
Tax % 9% 7% -123% 60% 18% -13% 4% -31% -32% -10% 28% 35%
57 61 5 1 -20 -27 -27 -8 54 49 29 30
EPS in Rs 54.21 53.27 3.98 1.05 -16.40 -21.54 -21.97 -6.67 43.97 36.65 21.67 22.82
Dividend Payout % 6% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 1%
5 Years: 14%
3 Years: 4%
TTM: 8%
Compounded Profit Growth
10 Years: -7%
5 Years: 30%
3 Years: 0%
TTM: 5%
Stock Price CAGR
10 Years: 3%
5 Years: 71%
3 Years: -2%
1 Year: 41%
Return on Equity
10 Years: 2%
5 Years: 7%
3 Years: 8%
Last Year: 6%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 11 11 11 11 12 12 12 12 12 13 13 13
Reserves 377 456 455 433 382 356 329 320 374 436 465 495
271 288 319 327 308 302 294 216 48 39 39 39
71 81 60 63 65 78 97 96 113 91 92 94
Total Liabilities 729 836 845 834 767 748 732 644 547 579 609 641
381 416 426 434 389 370 347 271 244 225 200 203
CWIP 48 68 78 80 66 65 65 25 25 25 26 21
Investments 29 29 29 29 29 0 0 0 0 0 20 19
272 323 312 291 283 314 320 348 277 329 363 398
Total Assets 729 836 845 834 767 748 732 644 547 579 609 641

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
51 53 67 42 62 52 44 78 132 41 28 35
-102 -94 -67 3 -18 -11 -11 -5 56 -17 -51 -7
55 39 -0 -46 -44 -40 -35 -72 -162 -9 0 0
Net Cash Flow 3 -2 -1 -0 0 0 -2 1 26 15 -23 28

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 43 44 49 50 41 45 38 34 12 19 58 57
Inventory Days 175 173 189 210 230 242 283 282 130 121 123 122
Days Payable 25 34 35 36 50 48 67 70 74 48 53 44
Cash Conversion Cycle 193 183 203 223 220 239 254 246 67 93 129 135
Working Capital Days 104 118 149 180 164 143 130 171 68 84 118 140
ROCE % 15% 13% 6% 5% 1% 2% 1% 3% 6% 10% 8%

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
40.81% 40.81% 40.81% 40.81% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76%
0.02% 0.10% 0.28% 0.33% 0.96% 1.13% 1.07% 1.00% 0.98% 1.03% 1.59% 1.48%
59.17% 59.09% 58.91% 58.86% 57.28% 57.11% 57.19% 57.26% 57.26% 57.21% 56.65% 56.76%
No. of Shareholders 14,41916,61718,23119,95221,18922,01522,24321,71920,49819,26719,56019,913

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings